Company intelligence / Profile preview

Xiamen Ganbaoli Biopharmaceutical

Xiamen, Fujian, China

Ownership: Private
Development stage: Other

Overview

Xiamen Ganbaoli Biopharmaceutical is a clinical-stage biotechnology company based in Xiamen, China, specializing in the development of therapeutic vaccines for chronic viral infections and liver diseases. The company's primary focus is achieving a functional cure for chronic Hepatitis B (CHB) through its lead candidate, GB-001, a recombinant therapeutic vaccine. Ganbaoli utilizes advanced protein engineering and immunological platforms to stimulate robust T-cell responses against the Hepatitis B virus. The firm operates within the Haicang Bio-bay and maintains collaborations with leading Chinese academic and clinical research centers.

Therapeutic areas: Infectious Diseases
Modalities: BiologicVaccineRecombinant protein
Industry: Biotech

Beyond the preview

Go deeper on Xiamen Ganbaoli Biopharmaceutical.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Xiamen Ganbaoli Biopharmaceutical.

Explore the full profile